Manufacturers Look to Vaccines for Growth and Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturers Look to Vaccines for Growth and Innovation
Vaccine R&D is surging, but continues to raise manufacturing and regulatory challenges.


Pharmaceutical Technology
Volume 34, Issue 2, pp. 30-37

Regulatory responses

The desire to develop more vaccines to meet global health needs has highlighted vaccine regulation in the US and abroad. Although FDA streamlined its testing and data requirements for H1N1-vaccine candidates, manufacturers would like to see a more coordinated international approval process. The WHO vaccine prequalification process takes approximately 18 months, in addition to all the work involved in licensing a product with FDA or European authorities.

FDA is working closely with WHO to improve this process. One idea is to couple US or European Union licensure of a new vaccine with WHO prequalification to spur world access to the new product, explained acting director of FDA's Center for Biologics Evaluation and Research Karen Midthun at a November conference on global vaccine development sponsored by the Drug Information Association. FDA is providing advice on clinical-trial issues for global vaccine development, helping to assess new technology for vaccine manufacture, and working with WHO to help build regulatory capacity in developing countries.

"We are poised for a transformation in how we produce and use influenza vaccine," Goodman said, noting that these efforts align with FDA's goal to strengthen the agency's scientific infrastructure, particularly for novel technologies and products that can improve public health. FDA is, for example, looking to use molecular biology to improve the way the agency assesses new influenza-virus strains and to test for potency, purity, and sterility in lot release.

A December 2009 report from the Institute of Medicine (IOM) urges a more coordinated US approach to vaccine development and safety monitoring under a strengthened National Vaccine Program Office. The program would target support for vaccine R&D to untreated diseases, focus more attention on vaccine safety issues, expand healthcare plan coverage for all recommended vaccines and better address fears and misinformation about vaccine effectiveness and safety.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here